Dr. Marc Hedrick | President and Chief Executive Officer |
Dr. Norman LaFrance | Chief Medical Officer |
Andrew Sims | Chief Financial Officer |
Michael Rabinowitz | Maxim Group |
Ed Woo | Ascendiant Capital |
Good afternoon, ladies and gentlemen. Welcome to the Plus Therapeutics Second Quarter 2022 Results Call.
Before we begin, we want to advise you that over the course of the call and question-and-answer session, forward-looking statements will be made regarding events, trends, business prospects and financial performance, which may affect Plus Therapeutics' future operating results and financial position. All such statements are subject to risks and uncertainties, including the risks and uncertainties described under the Risk Factors section included in the Plus Therapeutics' annual report on Form 10-K and quarterly report on Form 10-Q filed with the Securities and Exchange Commission from time to time. Plus Therapeutics advises you to review these risk factors in considering such statements.